Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
0
FDF
0
Weekly News Recap #Phispers
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Brand Name: Mounjaro
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Eli Lilly
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2024
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Aspen Announces Local Availability of Lilly’s Mounjaro
Details : Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.
Product Name : Mounjaro
Product Type : Peptide
Upfront Cash : Inapplicable
December 20, 2024
Details:
The net proceeds from the offering will be used to fund the developement of Vyleesi (bremelanotide acetate), which is being evaluated in mid-stage clinical trial studies for the treatment of obesity.
Lead Product(s): Bremelanotide Acetate,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Vyleesi
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Alliance Global Partners
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 07, 2025
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Alliance Global Partners
Deal Size : $23.0 million
Deal Type : Public Offering
Palatin Technologies Announces Pricing of up to $23 Million Public Offering
Details : The net proceeds from the offering will be used to fund the developement of Vyleesi (bremelanotide acetate), which is being evaluated in mid-stage clinical trial studies for the treatment of obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Undisclosed
May 07, 2025
Details:
Vyleesi (bremelanotide) is a melanocortin receptor agonist (MCR), which is being evaluated in combination with tirzepatide for obesity.
Lead Product(s): Bremelanotide Acetate,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Vyleesi
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 17, 2025
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin Sees Positive Appetite Suppression in Obesity Study with Bremelanotide Combo
Details : Vyleesi (bremelanotide) is a melanocortin receptor agonist (MCR), which is being evaluated in combination with tirzepatide for obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
April 17, 2025
Details:
Nimacimab is a first-in-class peripheral CB1-inhibiting antibody, being studied with the dual GLP-1/GIP agonist, tirzepatide for obesity.
Lead Product(s): Nimacimab,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 15, 2025
Lead Product(s) : Nimacimab,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Skye Shows 30% Weight Loss in Preclinical with Nimacimab Combo
Details : Nimacimab is a first-in-class peripheral CB1-inhibiting antibody, being studied with the dual GLP-1/GIP agonist, tirzepatide for obesity.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 15, 2025
Details:
Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for obesity.
Lead Product(s): Bremelanotide Acetate,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Vyleesi
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2025
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin's MC4R Agonist Bremelanotide with GLP-1/GIP Tirzepatide Hits Ph 2 Goal
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
March 31, 2025
Details:
Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Brand Name: Mounjaro
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2025
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eli Lilly Launches Weight-Loss Drug Mounjaro in India After Drug Regulator Approval
Details : Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.
Product Name : Mounjaro
Product Type : Peptide
Upfront Cash : Inapplicable
March 20, 2025
Details:
ARO-INHBE is a RNAi-based candidate, is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E, being developed for obesity and metabolic diseases.
Lead Product(s): ARO-INHBE,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: ARO-INHBE
Study Phase: Phase I/ Phase IIProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2025
Lead Product(s) : ARO-INHBE,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrowhead Showcases RNAi Candidates for Obesity, Metabolic Disorders
Details : ARO-INHBE is a RNAi-based candidate, is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E, being developed for obesity and metabolic diseases.
Product Name : ARO-INHBE
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 06, 2025
Details:
Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for obesity.
Lead Product(s): Bremelanotide Acetate,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Vyleesi
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2025
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
February 06, 2025
Details:
Zepbound (tirzepatide) injection is a first obstructive sleep apnea in adults with obesity treatment of its kind that activates both GIP/GLP-1 hormone receptors.
Lead Product(s): Tirzepatide
Therapeutic Area: Sleep Brand Name: Zepbound
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2024
Lead Product(s) : Tirzepatide
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Zepbound® (Tirzepatide) for Obstructive Sleep Apnea in Adults with Obesity
Details : Zepbound (tirzepatide) injection is a first obstructive sleep apnea in adults with obesity treatment of its kind that activates both GIP/GLP-1 hormone receptors.
Product Name : Zepbound
Product Type : Peptide
Upfront Cash : Inapplicable
December 20, 2024
Details:
Oral DehydraTECH-technology processed tirzepatide (GLP-1 + GIP agonist) is being investigated for diabetes mellitus and obesity.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Brand Name: DehydraTECH-tirzepatide
Study Phase: Phase IProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2024
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Details : Oral DehydraTECH-technology processed tirzepatide (GLP-1 + GIP agonist) is being investigated for diabetes mellitus and obesity.
Product Name : DehydraTECH-tirzepatide
Product Type : Peptide
Upfront Cash : Inapplicable
December 19, 2024
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE